2023
DOI: 10.1182/blood.2022018730
|View full text |Cite
|
Sign up to set email alerts
|

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

Abstract: This global, phase 3 study compared lisocabtagene maraleucel (liso-cel) with standard of care (SOC) as second-line therapy for primary refractory or early relapsed (≤12 months) large B-cell lymphoma (LBCL). Adults eligible for autologous stem cell transplantation (ASCT) were randomized 1:1 to liso-cel (100×106 CAR+ T cells) or SOC (3 cycles of platinum-based immunochemotherapy followed by high-dose chemotherapy and ASCT in responders). The primary end point was event-free survival (EFS) by independent review. … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

3
101
4
2

Year Published

2023
2023
2024
2024

Publication Types

Select...
5
1
1

Relationship

0
7

Authors

Journals

citations
Cited by 151 publications
(110 citation statements)
references
References 15 publications
3
101
4
2
Order By: Relevance
“…In this study and others, these tumors do not typically respond to further (immuno)chemotherapy-based salvage regimens and outcomes are poor, 3 while alternatives to chemotherapy have been shown to produce superior outcomes in this patient population. 41,42 The population of primary refractory patients should therefore be the focus in identifying both genetic and non-genetic mechanisms of resistance to front-line immunochemotherapy.…”
Section: Discussionmentioning
confidence: 99%
“…In this study and others, these tumors do not typically respond to further (immuno)chemotherapy-based salvage regimens and outcomes are poor, 3 while alternatives to chemotherapy have been shown to produce superior outcomes in this patient population. 41,42 The population of primary refractory patients should therefore be the focus in identifying both genetic and non-genetic mechanisms of resistance to front-line immunochemotherapy.…”
Section: Discussionmentioning
confidence: 99%
“…19 Furthermore, patients in TRANSFORM and BELINDA were permitted to receive one or multiple cycles of platinum-based salvage chemotherapy. 20,21 ZUMA-7 SOC patients were also only permitted to receive a single line of salvage chemotherapy compared to up to two in the other studies. 19 The gap between registration and infusion was also longer in BELINDA with a median time of 52 days, relative to 29 and 34 days in ZUMA-7 and TRANSFORM, respectively.…”
Section: Car T-cell Therapy In the Second-line For Lbclmentioning
confidence: 99%
“…[19][20][21] While all three trials used EFS as the primary endpoint, EFS was defined differently offering another potential explanation for discrepant results. [19][20][21] Investigation into the use of CAR T-cells in the second-line also extended to transplant-ineligible patients in the phase 2 PILOT study. 61 patients at a median age of 74 with r/r LBCL who experienced less than a CR to first-line chemoimmunotherapy received a single infusion of liso-cel.…”
Section: Car T-cell Therapy In the Second-line For Lbclmentioning
confidence: 99%
See 2 more Smart Citations